Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

Stephen Alexander Biography and Net Worth

SVP of Bicycle Therapeutics

Mr. Stephen Alexander is the SVP of Bicycle Therapeutics.

What is Stephen B. Alexander's net worth?: The estimated net worth of Stephen B. Alexander is at least $1.04 million as of January 17th, 2023. Mr. Alexander owns 70,561 shares of Bicycle Therapeutics stock worth more than $1,035,835 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Alexander may own. Learn More about Stephen B. Alexander's net worth.
How do I contact Stephen B. Alexander?: The corporate mailing address for Mr. Alexander and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Stephen B. Alexander's contact information.
Has Stephen B. Alexander been buying or selling shares of Bicycle Therapeutics?: Stephen B. Alexander has not been actively trading shares of Bicycle Therapeutics over the course of the past ninety days. Learn More on Stephen B. Alexander's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 32,657 shares worth more than $683,852.68. The most recent insider tranaction occured on December, 16th when Director Bros. Advisors Lp Baker bought 500,000 shares worth more than $7,670,000.00. Insiders at Bicycle Therapeutics own 8.5% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 12/16/2024.

Stephen B. Alexander Insider Trading History at Bicycle Therapeutics

Stephen B. Alexander Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $14.68

$14.64

$15.30

50 Day Range

MA: $21.83

$13.81

$27.51

2 Week Range

Now: $14.68

$12.17

$28.67

Volume

346,432 shs

Average Volume

404,265 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Cackling Kamala hates this company

From DTI | Ad